Artigo Revisado por pares

In-Vitro Stability, Metabolism, and Transport of Dental Monomers Made from Bisphenol A and Bisphenol F

2002; Wiley; Volume: 2; Issue: 8 Linguagem: Inglês

10.1002/1616-5195(200211)2

ISSN

1616-5195

Autores

Steve Burmaster, Robert E. Smith, David Eick, Elisabet L. Kostoryz, David M. Yourtee,

Tópico(s)

Effects and risks of endocrine disrupting chemicals

Resumo

Macromolecular BioscienceVolume 2, Issue 8 p. 365-379 Full Paper In-Vitro Stability, Metabolism, and Transport of Dental Monomers Made from Bisphenol A and Bisphenol F Steve Burmaster, Steve Burmaster School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.Search for more papers by this authorRobert Smith, Robert Smith School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.Search for more papers by this authorDavid Eick, David Eick School of Dentistry, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.Search for more papers by this authorElisabet L. Kostoryz, Elisabet L. Kostoryz School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.Search for more papers by this authorDavid Yourtee, Corresponding Author David Yourtee [email protected] School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A. Fax: +1 816 235 1776Search for more papers by this author Steve Burmaster, Steve Burmaster School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.Search for more papers by this authorRobert Smith, Robert Smith School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.Search for more papers by this authorDavid Eick, David Eick School of Dentistry, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.Search for more papers by this authorElisabet L. Kostoryz, Elisabet L. Kostoryz School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.Search for more papers by this authorDavid Yourtee, Corresponding Author David Yourtee [email protected] School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A.School of Pharmacy, University of Missouri—Kansas City, Kansas City, MO 64108, U.S.A. Fax: +1 816 235 1776Search for more papers by this author First published: 19 December 2002 https://doi.org/10.1002/1616-5195(200211)2:8 3.0.CO;2-LCitations: 6Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract The stability and bioavailability of the biomaterial monomers, bisglycidyl methacrylate (BISGMA), bisphenol F diglycidyl ether (BFDGE), and bisphenol A dimethacrylate (BPADM) were investigated using in-vitro techniques. A reverse-phase high-pressure liquid chromatographic/mass spectrometric (HPLC/MS) system was developed to quantitate each monomer and its primary metabolite. Each monomer (10 × 10−6 M) was incubated at 37 °C under various conditions. Aliquots (N = 3) were removed at various time intervals and quantitated from a standard curve. The in-vitro transport of each parent monomer and its tetrahydroxy metabolite was measured in a Caco-2 system. BISGMA and BPADM were stable in aqueous solution at pH 1. However, BFDGE, was unstable. Plasma esterase of the rat rapidly hydrolyzed the ester compounds, but human esterase did not have a hydrolytic effect on BISGMA or BPADM. BFDGE disappeared in both rat and human plasma, but no tetrahydroxy metabolite was observed. All three parent compounds were unstable in human- and rat-hepatic fractions producing either tetrahydroxy metabolites or bisphenol A (BPA). The tetrahydroxy metabolites, however, were relatively stable under identical conditions, but BPA disappeared when incubated in hepatic-microsomal fractions. While BPADM metabolism produced BPA, an estrogen disrupter, BISGMA and BFDGE did not appear to produce BPA. These results suggest that the potential toxicity of leached dental monomers is more likely to be a result of the metabolite rather than the parent monomer. From Caco-2 transport studies, BFDGE and its tetrahydroxy metabolite both crossed the Caco-2 membrane at a low rate of transport in 2 h (approximately 3 and 5.2%, respectively). The BISGMA metabolite crossed at approximately 8%, indicative of a moderate rate of transport, and BPA crossed at approximately 10% in 1 h (high rate of transport). The transport of BPADM and BISGMA was unable to be determined due to nonspecific absorption to the acrylic vertical transport well. The transport of BFDGE tetrahydroxy metabolite is of particular interest as BFDGE is likely to be chemically hydrolyzed in stomach acid. It is well known that epoxies react with acids resulting in ring opening, so it is not surprising that BFDGE decomposes at pH 1. As a result, it is necessary to identify the decomposition (hydrolysis) products and test their bioavailability. Mean (SD) stability of BISGMA (10 × 10−6 M) and bisphenol A tetrahydroxy metabolite in human- and rat-S9-hepatic fractions at 37 °C for 1 h. References 1 C. A. May, Y. Tanaka, " Epoxy Resins", Marcel Dekker, New York 1973. 2 R. S. Bauer, " Epoxy Resin Chemistry II", American Chemical Society, Washington, DC 1983. 3 M. G. Buonocore, J. Dent. Res. 1955, 34, 849. 4 R. L. Bowen, J. Dent. Res. 1956, 35, 360. 5 U.S. 3 066 112 (1962), invs.: R. L. Bowen. 6 R. L. Bowen, J. Am. Dent. Assoc. JADA 1963, 66, 57. 7 L. Tao, D. H. Pashley, L. Boyd, Dent. Mater. 1988, 4, 208. 8 N. Nakabayashi, K. Kojima, E. Masuhara, J. Biomed. Mater. Res. 1982, 16, 265. 9 E. Munksgaard, E. Asmussen, J. Dent. Res. 1984, 63, 1087. 10 T. Suzuki, W. Finger, Dent. Mater. 1988, 4, 379. 11 U.S. 2 558 139 (1952), L. D. Caulk Company, Milford, De, invs.: F. E. Knock, J. F. Glenn. 12 R. G. Craig, Dent. Clin. North Am. 1981, 25, 219. 13 P. T. Triolo, E. J. Swift, Dent. Mater. 1992, 8, 370. 14 R. L. Cooley, E. Y. Tseng, W. W. Barkmeier, Quintessence Int. 1991, 22, 979. 15 J. S. Rees, P. H. Jacobson, Dent. Mater. 1989, 5, 41. 16 E. J. Swift, J. Am. Dent. Assoc. JADA 1991, 3, 91. 17 R. D. Norman, J. S. Wright, R. J. Rydberg, J. Prosthet. Dent. 1990, 64, 523. 18 D. M. Barnes, L. W. Blank, V. P. Thompson, Quintessence Int. 1991, 22, 143. 19 L. H. Keith, " Environmental Endocrine Disruptors: A Handbook of Property Data", John Wiley & Sons, New York 1997, p. 261. 20 J. A. Brotons, M. F. Olea-Serrano, M. Villalobos, V. Pedraza, N. Olea, Environ. Health Perspect. 1995, 106, 608. 21 K. F. Leinfelder, J. Am. Dent. Assoc. JADA 1995, 126, 663. 22 J. Bitman, H. C. Cecil, J. Agric. Food Chem. 1970, 18, 1108. 23 A. V. Krishman, P. Starhis, S. F. Permuth, L. Tokes, D. Feldman, Endocrinology 1998, 132, 2279. 24 J. Ashby, R. W. Tennant, Mutat. Res. 1988, 204, 17. 25 R. Steinmetz, N. A. Mitchner, A. Grant, D. L. Allen, R. M. Bigsby, N. Ben-Jonathan, Endocrinology 1998, 139, 2741. 26 J. B. Colerangle, D. Roy, J. Steroid Biochem. Mol. Biol. 1997, 60, 153. 27 N. Hanioka, H. Jinno, T. Nishimura, M. Ando, Arch. Toxicol. 1998, 72, 387. 28 F. S. Vom Saal, P. S. Cooke, D. L. Buchanan, P. Palanza, K. A. Thayer, S. C. Nagel, Toxicol. Ind. Health 1998, 14, 239. 29 K. W. Gaido, L. S. Leonard, S. Lovell, J. C. Gould, D. Babai, C. J. Portier, D. P. McDonnell, Toxicol. Appl. Pharmacol. 1997, 143, 205. 30 G. G. J. M. Kuiper, B. Carlsson, K. Gradien, Endocrinology 1997, 138, 863. 31 J. L. Ferracane, J. Oral Rehabil. 1994, 21, 441. 32 M. Freund, E. C. Munksgaard, Scand. J. Dent. Res. 1990, 98, 351. 33 A. J. De Gee, S. L. Wendt, A. Werner, C. L. Davidson, Biomaterials 1996, 17, 1327. 34 R. E. Smith, J. D. Eick, D. M. Yourtee, J. Liq. Chromatogr. Relat. Technol. 2001, 24, 531. 35 R. G. Dickinson, P. V. Baker, M. E. Frankilin, W. D. Hooper, J. Pharm. Sci. 1991, 80, 952. 36 D. J. Brayden, Pharm. News 1997, 4, 11. 37 B. Oray, H. S. Lu, R. W. Gracy, J. Chromatogr. 1983, 270, 253. 38 B. Grego, M. T. W. Hearn, J. Chromatogr. 1983, 255, 67. 39 N. Olea, R. Pulgar, P. Perez, M. F. Olea-Seerrano, A. Novillo-Fertrell, A. Reivas, A. Novillo-Fertrell, V. Pedraza, A. M. Soto, Environ. Health Perspect. 1996, 104, 298. 40 F. M. Williams, Clin. Pharmacokinet. 1987, 10, 392. 41 R. Mentlein, S. Heiland, E. Heymann, Arch. Biochem. Biophys. 1980, 200, 547. 42 D. J. Ecobichon, Res. Commun. Chem. Pathol. Pharmacol. 1972, 3, 629. 43 J. G. Spenney, R. M. Nowell, Drug Metab. Dispos. 1979, 7, 215. 44 D. Lombardo, O. Guy, Biochim. Biophys. Acta. 1980, 611, 136. 45 K. Cain, E. Reiner, D. G. Williams, Biochem. J. 1983, 215, 91. 46 J. Oertel, R. Wirthmuller, M. Kastner, Blut 1983, 46, 101. 47 N. Hojring, O. Svensmark, Biochim, Biophys. Acta 1977, 481, 500. 48 A. Pannatier, B. Testa, J. C. Etter, Int. J. Pharm. 1981, 8, 167. 49 E. Heymann, " Metabolic Basis of Detoxication, Metabolism of Functional Groups", Academic Press, New York 1982, p. 229. 50 W. N. Aldridge, Biochem. J. 1953, 53, 117. 51 O. Svensmark, Acta Physiol. Scand. 1965, 64, 1. 52 O. Lockridge, C. F. Bartels, T. A. Vaughan, J. Biol. Chem. 1987, 262, 549. 53 O. Lockridge, Pharmacol. Ther. 1990, 47, 35. 54 F. M. Williams, E. M. Mutch, E. Nicholson, H. Wynne, P. Wright, D. Lambert, M. D. Williams, J. Pharm. Pharmacol. 1989, 41, 407. 55 F. M. Williams, Clin. Pharmacokinet. 1985, 10, 392. 56 B. W. H. Leung, L. Shajii, F. Jaffer, J. P. Santerre, J. Dent. Res. 1997, 76, 321. 57 J. P. Santerre, L. Shajii, H. Tsang, J. Dent. Res. 1999, 78, 1459. 58 C. D. Klaassen, " Casarett and Doull's Toxicology The Basic Science of Poisons", 5th edition, McGraw-Hill, New York 1996, p. 214. 59 D. Arenholt-Bindslev, V. Breinholt, G. Schmalz, A. Preiss, J. Dent. Res. 1998, 77, 692. 60 Y. K. Fung, N. O. Ewoldsen, H. A. St. Germain, C. Miaw, N.-H. Chou, S. E. Gruninger, F. C. Eichmiller, C. Siew, J. Dent. Res. 1999, 78, 270. 61 H. Vankerchkhoven, P. Lambrechrs, M. Van Beylan, G. Vanherle, J. Dent. Res. 1981, 60, 1957. 62 K. Inoue, I. Hayashi, J. Oral Rehabil. 1982, 9, 493. 63 M. M. A. Rathbun, R. G. Craig, C. T. Hanks, F. E. Filisko, J. Biomed. Mater. Res. 1991, 25, 443. 64 I. E. Ruyter, S. A. Svendsen, Acta Odontol. Scand. 1977, 36, 75. 65 A. Hamid, W. R. Hume, Dent. Mater. 1997, 13, 98. 66 D. Nathanson, P. Lertpitayakun, M. S. Lamkin, E. B. Mahnaz, L. Lee-Chou, J. Am. Dent. Assoc. JADA 1997, 128, 1517. 67 C. T. Hanks, S. E. Strawn, J. C. Wataha, R. G. Craig, J. Dent. Res. 1991, 69, 1450. 68 A. Atkinson, D. Roy, Environ. Mol. Mutagen. 1995, 26, 60. 69 G. Schmalz, A. Preiss, D. Arenholt-Bindlev, J. Dent. Res. 1998, 77, 823. 70 J. B. Knaak, L. J. Sullivan, Toxicol. Appl. Pharmacol. 1966, 8, 175. 71 L. H. Pottenger, J. Y. Domoradzki, D. A. Markham, S. C. Hansen, S. Z. Cagen, J. M. Waechter, Jr., Toxicol. Sci. 2000, 54, 3. 72 R. W. Snyder, S. C. Maness, K. W. Gaido, F. Welsch, S. C. J. Summer, T. R. Fennell, Toxicol., Appl. Pharmacol. 2000, 168, 225. 73 A. V. Krishnan, P. Strahis, S. F. Permuth, L. Tokes, D. Feldman, Endocrinology 1993, 132, 2279. 74 J. A. Carrillo, S. I. Ramos, J. A. G. Agundex, C. Martinez, J. Benitez, Ther. Drug Monit. 1998, 20, 319. 75 E. Vielnascher, M. Spatzenegger, A. Mayrhofer, P. Klinger, W. Jager, Pharmazie 1996, 51, 586. 76 J. K. Beetham, D. Grant, M. Arand, J. Gargarino, T. Kiyosue, F. Pinot, F. Oesch, W. R. Belknap, K. K. Shinozaki, B. D. Hammock, DNA Cell Biol. 1995, 14, 61. 77 A. Sevanian, L. L. McLeod, J. Biol. Chem. 1986, 261, 54. 78 C. R. Pace Asciak, W. S. Lee, J. Biol. Chem. 1989, 264, 9310. 79 J. Y. Fu, J. Haeggstrom, P. Collins, J. Meijer, O. Radmark, Biochim. Biophys. Acta 1989, 1006, 121. 80 J. K. Beetham, T. Tian, B. D. Hammock, Arch. Biochem. Biophys. 1993, 305, 197. 81 R. C. Skoda, A. Demierre, Q. W. McBride, F. J. Gonzalez, U. A. Meyer, J. Biol. Chem. 1988, 263, 1549. 82 N. M. Bjelogrlic, M. Makinen, F. Stenback, K. Vahakangas, Carcinogenesis 1994, 15, 771. 83 D. C. Zeldin, J. Kobayashi, J. R. Falck, B. S. Winder, B. D. Hammock, J. R. Snapper, J. H. Capdevila, J. Biol. Chem. 1993, 268, 6402. 84 D. C. Zeldin, S. Wei, J. R. Falck, B. D. Hammock, J. R. Snapper, J. H. Capdevila, Arch. Biochem. Biophys. 1995, 316, 443. 85 J. Z. Haeggstrom, A. Wetterholm, J. F. Medina, B. Samuelsson, Adv. Prostaglandin, Thromboxane, Leukotriene. Res. 1994, 22, 3. 86 J. M. Sayer, H. Yagi, P. J. van Balderen, W. Levin, D. M. Jerina, J. Biol. Chem. 1985, 260, 1630. 87 A. W. Wood, R. L. Chang, W. Levin, S. Kumar, N. Shirai, D. M. Jerina, R. E. Lehr, A. H. Conney, Cancer Res. 1986, 46, 2760. 88 R. Gasser, Exp. Toxicol. Pathol. 1996, 48, 467. 89 S. M. Rappaport, K. Yeowell-O'Connell, W. Bodell, J. W. Yager, E. Symanski, Cancer Res. 1996, 56, 5410. 90 F. P. Guengerich, Rev. Biochem. Toxicol. 1982, 4, 5. 91 I. J. G. Climie, D. H. Hutson, G. Stoydin, Xenobiotica 1981, 11, 391. 92 I. J. G. Climie, D. H. Hutson, G. Stoydin, Xenobiotica 1981, 11, 401. 93 P. Bentley, F. Bieri, H. Kuster, S. Muakkassah-Kelly, P. Sagelsdorff, W. Staubli, F. Waechter, Carcinogenesis 1989, 10, 321. 94 A. Atkinson, D. Roy, Toxicologist 1993, 32, 111. 95 A. Atkinson, D. Roy, Environ. Mol. Mutagen. 1995, 26, 60. 96 H. Yokata, H. Iwano, M. Endo, T. Kobayashi, H. Inoue, S. Ikushiro, A. Yuasa, Biochem. J. 1999, 340, 405. 97 J. Fogh, J. M. Fogh, T. Orfeo, J. Natl. Cancer Inst. 1977, 59, 221. 98 M. Pinto, S. Robin-Leon, M. D. Appay, M. Kedinger, N. Triadou, E. Dussaulx, B. Lacroiz, P. Simon-Assmann, K. Haffen, J. Fogh, A. Zweibaum, Biol. Cell 1983, 47, 323. 99 E. Grasset, M. Pinto, E. Dussaulx, A. Zweibaum, J. F. Desjeux, Am. J. Physiol. 1984, 247, C260. 100 I. J. Hidalgo, T. J. Raub, R. T. Borchardt, Gastroenterology 1989, 96, 736. 101 P. Artursson, J. Pharm. Sci. 1990, 79, 476. 102 A. R. Hilger, R. A. Conradi, P. S. Burton, Pharm. Res. 1990, 7, 902. 103 J. N. Cogurn, M. G. Donovan, C. S. Schasteen, Pharm. Res. 1991, 8, 210. 104 W. H. Peters, H. M. J. Roelofs, Cancer Res. 1992, 82, 1886. 105 G. K. Collington, J. Hunter, C. N. Allen, N. L. Simmons, B. H. Hirst, Biochem. Pharmacol. 1992, 44, 417. 106 K. Y. Ng, R. T. Borchardt, Life Sci. 1993, 53, 1121. 107 I. J. Hidalgo, A. Kato, R. T. Borchardt, Biochem. Biophys. Res. Commun. 1989, 160, 317. 108 R. P. J. Oude Elferink, C. T. M. Bakker, P. L. Jansen, Biochem. J. 1993, 290, 759. 109 E. K. Anderberg, P. Artursson, J. Pharm. Sci. 1993, 82, 392. 110 A. S. Tang, P. J. Chikhale, P. K. Shah, R. T. Borchardt, Pharm. Res. 1993, 10, 1620. 111 P. Artursson, J. Karlsson, Biochem. Biophys. Res. Commun. 1991, 175, 880. Citing Literature Volume2, Issue8November 2002Pages 365-379 ReferencesRelatedInformation

Referência(s)
Altmetric
PlumX